Non-Pharmacological Methods in Reducing Injection Pain
Randomized
Comparison of the Effectiveness of Different Non-Pharmacological Methods in Reducing Injection Pain in Preschool Children: Randomized Controlled Trial
1 other identifier
interventional
120
1 country
1
Brief Summary
In emergency departments, various methods can be used to reduce the pain experienced by children. However, the most important requirement is that the selected method provides rapid and effective results. Accordingly, it is essential that interventions performed in emergency settings are carried out in a way that enables children to experience the least possible pain and anxiety and that the long-term effects of pain are prevented. Recently, the Helfer Skin Tap Technique (HSTT), which is applied to reduce stress and pain, and the palm stimulator, which is held in the palm and has raised projections on its surface to reduce pain perception by facilitating distraction, have attracted attention. ShotBlocker is a noninvasive, U-shaped plastic device with small projections that is used to reduce injection-related pain in children who are sensitive to pain. In addition, a bee-shaped device called Buzzy®, which combines external cold application and vibration, is also widely used. These methods have been proven to be effective in reducing pain in pediatric patients during invasive procedures such as intramuscular injections and intravenous cannulation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable pain
Started Dec 2025
Shorter than P25 for not_applicable pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2026
CompletedFirst Submitted
Initial submission to the registry
January 17, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
January 17, 2026
CompletedFirst Posted
Study publicly available on registry
January 26, 2026
CompletedJanuary 26, 2026
January 1, 2026
21 days
January 17, 2026
January 17, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Pain Rating Scale
The Wong-Baker FACES Pain Rating Scale was used to assess self-reported pain levels. This scale consists of six facial expressions ranging from "no hurt" (0) to "hurts worst" (10), allowing children to select the face that best represents their level of pain.
6 weeks
Study Arms (4)
intervention group Palm
EXPERIMENTALPalm stimulator
intervention group ShotBloker
EXPERIMENTALShotBloker device
intervention group HSTT
EXPERIMENTALHSTT application
Control group
NO INTERVENTIONRutin
Interventions
ShotBlocker is a flat, horseshoe-shaped device used to reduce pain during subcutaneous or intramuscular (IM) injections. It features short, blunt, non-sharp projections approximately 2 mm in height and is designed to be placed against the skin, with a central opening that exposes the injection site. The device is applied to the skin just prior to injection, with its textured surface making contact with the skin. Although the projections do not penetrate the skin, they are believed to create a sensory stimulus associated with pain modulation based on the gate control theory.
Helfer Skin Tap Technique: After determining the injection site, gently tap the skin several times with the fingertips of the dominant (most commonly used) hand for approximately 5 seconds to relax the muscle. After the skin is wiped with antiseptic solution and stretched, the cap of the syringe in the dominant (most commonly used) hand is opened. A large V is made with the thumb and index finger of the non-dominant hand. The skin is tapped three times quickly using the whole hand to stimulate the major muscle fibers. The nurse/midwife counts to 3, and the needle is inserted into the muscle at a 90-degree angle simultaneously. To remove the needle from the skin, the skin is tapped three times quickly (again in a V shape) with the whole non-dominant hand, and the needle is withdrawn simultaneously with the final tap (tapping).
The Palm Stimulator is 1.6 cm in diameter and 4 cm in length, and has a cylindrical, non-slip, and easy-to-grip structure designed to maximize palm contact. The Palm Stimulator is used by gripping it in the palm during injection. The device has blunt protrusions all around the palm to provide tactile stimulation. These blunt protrusions do not penetrate the skin but, according to gate control theory, create stimulation and close the pain gate in the spinal cord, reducing the pain perceived during injection. The researcher will show the Palm Stimulator, the device providing tactile stimulation, and allow examination. Twenty seconds before the injection, the Palm Stimulator will be placed in the palm of the child's dominant hand so that the child can grasp it. The child will be instructed to hold the device firmly in their palm throughout the procedure. After the injection is complete, the device will be removed from the child.
Eligibility Criteria
You may qualify if:
- Children aged between 4 and 6 years,
- An intramuscular (IM) medication order was prescribed by a physician,
- The IM injection was administered in the pediatric emergency department,
- No history of chronic pain-causing illness,
- No diagnosis of neurodevelopmental disorders,
- Had not received any analgesic medications in the past 6 hours,
- No history of syncope (fainting) during previous injections,
- No diagnosis of mental retardation,
- No scar tissue or muscle atrophy at the intended injection site,
- Body mass index (BMI) percentile between the 10th and 90th percentiles for age and gender,
- Both child and parent provided informed consent to participate in the study.
You may not qualify if:
- Participants were excluded from the study if:
- The child was younger than 4 or older than 6 years,
- There was scar tissue or muscle atrophy at the injection site,
- The child or parent had communication difficulties,
- The child's BMI was below the 10th percentile (cachectic) or above the 90th percentile (obese),
- Either the child or parent declined to participate in the research.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sakarya University
Sakarya, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
January 17, 2026
First Posted
January 26, 2026
Study Start
December 25, 2025
Primary Completion
January 15, 2026
Study Completion
January 17, 2026
Last Updated
January 26, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
Ethically, patient information can be shared upon reasonable request without revealing their identities for security reasons